Leveraging Technology, Safeguarding IP, and Securing Funding to Accelerate Development in RNA, Gene Editing Tech and Regenerative Medicines-
-
20/03/2025 21/03/2025 America/Toronto Novel Therapeutic Modalities Novel Therapeutic Modalities
March 20 – 21, 2025
Boston, MA
Please visit https://www.americanconference.com/novel-therapies/ for more information and updates. Boston, MA true DD/MM/YYYY 1440 use-title -
-
-
20/03/2025 21/03/2025 America/Toronto Novel Therapeutic Modalities Novel Therapeutic Modalities
March 20 – 21, 2025
Boston, MA
Please visit https://www.americanconference.com/novel-therapies/ for more information and updates. Boston, MA true DD/MM/YYYY 1440 use-title -
Our 2024 event has concluded.
Thank you to those who joined us in Boston!
Stay tuned for more information about our upcoming event. We look forward to bringing you another exceptional conference next year and look forward to returning in March 2025!
OUR 2025 PROGRAM IS IN DEVELOPMENT
2024 FDA Keynote Speaker
Julie Tierney
Deputy Center Director, Center for Biologics Evaluation and Research
FDA
2024 IN-HOUSE INSIGHTS FROM
- Abata Therapeutics
- Argenx
- Beam Therapeutics
- Caribou Biosciences, Inc.
- Dyno Therapeutics
- Novo Nordisk
- ReNAgade Therapeutics
- Rocket Pharmaceuticals, Inc.
- Vertex Pharmaceuticals
2024 Conference Co-Chairs
Cristin Berkey
VP, IP and Legal Affairs
Abata Therapeutics
(2024 Advisory Board Member)
Forrester Liddle
Head of Intellectual Property and Legal, US R&D
Novo Nordisk
(2024 Advisory Board Member)
Adrian Looney
Chief Intellectual Property Counsel
Vertex Pharmaceuticals
(2024 Advisory Board Member)
2024 Advisory Board
Elbert Chiang
VP, IP
Beam Therapeutics
Gabriel J. McCool
VP, Legal and IP
ReNAgade Therapeutics
Sharick Naqi
Director & Senior Counsel
Global IP Lead – Gene Therapies
Novartis Gene Therapies
David H. Silverstein
Vice President, Intellectual Property
Rocket Pharmaceuticals, Inc.
Lulu Wang
Head of IP
Orna Therapeutics
Olga Zimmerman
Director, Intellectual Property
Caribou Biosciences, Inc.
ABOUT THE CONFERENCE
American Conference Institute is pleased to present the 3rd Annual Forum on IP, Funding, and Tech Strategies for Novel Therapeutic Modalities, where the brightest minds in RNA, gene editing, and regenerative medicine converge to shape the future of this rapidly evolving field.
Positioned at the critical juncture of innovation and commercialization, this premier event is dedicated to unraveling the complex interplay of evolving market trends, dynamic regulatory frameworks, and critical intellectual property strategies.
Join us in Boston in this collaborative endeavor to drive forward the most groundbreaking advancements in novel therapeutics, marrying scientific discovery with strategic business acumen for global impact.
Attend to engage with leading industry thought leaders and legal pioneers who will illuminate the path from groundbreaking research to global market success. Here, we explore in-depth the nuances of funding methodologies, AI’s transformative role in drug discovery, and the intricacies of navigating the legal and regulatory landscapes.
CLE Accreditation
Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation. Learn More
Related Conferences
